According to the U.S. Food and Drug Administration, an initial examination of adverse reactions associated with commonly prescribed medications for diabetes and obesity did not reveal any correlation with suicidal ideation or behavior. This announcement was made on Thursday.

However, the agency also stated that they are unable to completely dismiss the possibility of “a slight risk” and will continue to investigate reports about over 12 medications, such as Ozempic, Wegovy, and Mounjaro. The FDA advised patients taking these drugs to inform their healthcare providers of any concerns.

A recent study, funded by the government, found that individuals who took semaglutide, the medication used in Ozempic and Wegovy, had a lower chance of experiencing suicidal thoughts compared to those taking other medications for obesity and diabetes. This review was prompted by European regulators who were looking into reports of individuals on semaglutide having thoughts of self-harm.

According to the FDA report, our initial assessment did not discover proof that the use of these medications leads to suicidal thoughts or behaviors.

The organization is examining records concerning over twelve drugs that were authorized after 2005 and are referred to as GLP-1 receptor agonists. These medications assist in regulating blood sugar levels and decreasing the chances of heart disease in individuals with type 2 diabetes. Additionally, some of these drugs are utilized to aid individuals with obesity or who are overweight in losing weight.

___

The Health and Science Department of the Associated Press is supported by the Science and Educational Media Group of the Howard Hughes Medical Institute. The AP is solely responsible for the creation of all content.